Certara Sees Unusually Large Options Volume (NASDAQ:CERT)

Certara, Inc. (NASDAQ:CERT) was the target of some unusual options trading activity on Tuesday. Stock traders purchased 6,462 call options on the company. This is an increase of 4,617% compared to the average volume of 137 call options.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Barclays lifted their target price on shares of Certara from $6.50 to $7.50 and gave the company an “equal weight” rating in a report on Wednesday, August 5th. UBS Group restated a “neutral” rating and set a $10.00 price target on shares of Certara in a research report on Wednesday, September 30th. Finally, Weiss Ratings raised Certara from a “sell (e+)” rating to a “sell (d)” rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.45.

Certara Stock Down 4.4%

CERT stock traded down $0.44 during mid-day trading on Tuesday, reaching $9.63. The company had a trading volume of 950,851 shares, compared to its average volume of 3,492,791. The firm has a fifty day simple moving average of $8.32 and a 200 day simple moving average of $6.78. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.55 and a current ratio of 2.55. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of -21.30 and a beta of 1.42. Certara has a fifty-two week low of $4.45 and a fifty-two week high of $13.52.

Certara (NASDAQ:CERT) last released its earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The firm had revenue of $93.27 million for the quarter, compared to analysts’ expectations of $98.09 million. Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.The firm’s quarterly revenue was down 10.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.07 earnings per share. Analysts forecast that Certara will post 0.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Certara

A number of large investors have recently modified their holdings of CERT. Integrated Wealth Concepts LLC acquired a new stake in shares of Certara in the 2nd quarter valued at $39,000. NorthRock Partners LLC acquired a new position in shares of Certara during the second quarter worth $68,000. State of Wyoming purchased a new position in Certara in the second quarter valued at $72,000. Perigon Wealth Management LLC purchased a new position in Certara in the second quarter valued at $80,000. Finally, Quantbot Technologies LP acquired a new stake in Certara in the second quarter valued at $82,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Company Profile

Certara, Inc (NASDAQ:CERT) provides software and technology-enabled services for the biopharmaceutical industry. The company helps drug developers use regulatory science, data analysis, and modeling and simulation to support decisions throughout the research, development, and commercialization lifecycle.

Its offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial design, patient and disease modeling, regulatory submissions, and real-world data analysis.